Injection of GIP and GLP-2 may reduce bone resorption biomarker CTX in type 2 diabetes patients: Study
Denmark: A recent study published in The Journal of Clinical Endocrinology and Metabolism has shed light on the effects of exogenous glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) on burn turnover in patients with type 2 diabetes (T2D).
The researchers revealed that the acute effects of exogenous GIP and GLP-2 on bone turnover are also present in patients with T2D, presenting a promising avenue for exploring novel treatment options that could potentially reduce the risk of fractures linked with type 2 diabetes.
"Subcutaneous GIP and GLP-2 affect the bone resorption markers, collagen type 1 C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) in individuals with T2D to the same extent as previously demonstrated in healthy individuals," Kirsa Skov-Jeppesen, University of Copenhagen, Copenhagen, Denmark, and colleagues wrote.
Individuals with type 2 diabetes are at increased risk of bone fractures despite normal or increased bone mineral density (BMD). There is no clear understanding of the underlying causes, but could include disturbances in the gut-bone axis, in which GIP and GLP-2 are regulators of bone turnover. Thus, in healthy fasting participants both exogenous GLP-2 and GIP reduce bone resorption.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.